William Blair Reiterates “Market Perform” Rating for Poseida Therapeutics (NASDAQ:PSTX)

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “market perform” rating reiterated by equities researchers at William Blair in a research report issued on Tuesday, MarketBeat.com reports.

Separately, HC Wainwright reissued a “neutral” rating and set a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Stock Performance

PSTX stock opened at $9.33 on Tuesday. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $909.35 million, a price-to-earnings ratio of -14.81 and a beta of 0.54. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $9.42. The firm has a 50 day moving average of $3.02 and a two-hundred day moving average of $3.01.

Insider Transactions at Poseida Therapeutics

In other news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now owns 651,291 shares in the company, valued at approximately $6,037,467.57. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.90% of the company’s stock.

Institutional Trading of Poseida Therapeutics

Several institutional investors have recently made changes to their positions in PSTX. Marshall Wace LLP acquired a new stake in shares of Poseida Therapeutics during the 2nd quarter valued at about $31,000. Bayesian Capital Management LP acquired a new stake in shares of Poseida Therapeutics during the 1st quarter valued at about $33,000. Rothschild Investment LLC acquired a new stake in shares of Poseida Therapeutics during the 2nd quarter valued at about $35,000. Principal Financial Group Inc. acquired a new stake in shares of Poseida Therapeutics during the 2nd quarter valued at about $35,000. Finally, Virtu Financial LLC acquired a new stake in shares of Poseida Therapeutics during the 3rd quarter valued at about $37,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.